Targeting PI3Kgamma dependency in leukemia treatment [PI3Kgamma inhibition]
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 18 samples: 6 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targetable leukaemia dependency on noncanonical PI3Kγ signallingNature · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE243654_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1019338 and SRA study SRP463098. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 18 samples.
How we read this: 6 replicated groups read from 18 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7792347 NTC#1-Rep1 NTC#1
- GSM7792348 NTC#1-Rep2 NTC#1
- GSM7792349 NTC#2-Rep1 NTC#2
- GSM7792350 NTC#2-Rep2 NTC#2
- GSM7792351 NTC#1+PI3Kγi-Rep1 NTC#1+PI3Kγi
- GSM7792352 NTC#1+PI3Kγi-Rep2 NTC#1+PI3Kγi
- GSM7792353 NTC#2+PI3Kγi-Rep1 NTC#2+PI3Kγi
- GSM7792354 NTC#2+PI3Kγi-Rep2 NTC#2+PI3Kγi
- GSM7792355 PIK3R5i#1-Rep1 PIK3R5i#1
- GSM7792356 PIK3R5i#1-Rep2 PIK3R5i#1
- GSM7792357 PIK3R5i#1-Rep3 PIK3R5i#1
- GSM7792358 PIK3R5i#1-Rep4 PIK3R5i#1
- GSM7792359 PIK3R5i#1-Rep5 PIK3R5i#1
- GSM7792360 PIK3R5i#2-Rep1 PIK3R5i#2
- GSM7792361 PIK3R5i#2-Rep2 PIK3R5i#2
- GSM7792362 PIK3R5i#2-Rep3 PIK3R5i#2
- GSM7792363 PIK3R5i#2-Rep4 PIK3R5i#2
- GSM7792364 PIK3R5i#2-Rep5 PIK3R5i#2
- GSE320438 A novel nanobody-based TCR-like CAR-T therapy targeting PRAME for the treatment of acute myeloid leukemia 12 samples shares targeting, treatment, leukemia
- GSE281506 Combining Menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia 42 samples shares inhibition, leukemia
- GSE331214 Single-cell profiling across treatment stages enables precision targeting of therapy-resistant neuroblastoma 38 samples shares targeting, treatment
- GSE78220 mRNA expressions in pre-treatment melanomas undergoing anti-PD-1 checkpoint inhibition therapy 28 samples shares inhibition, treatment
- GSE260759 Targeting a Lineage-Specific PI3Kɣ/AKT Signaling Module in Acute Myeloid Leukemia Using a Heterobifunctional Degrader Molecule 24 samples shares targeting, leukemia
- GSE305560 TP53-Agnostic Lethality through Combined Pan-HDAC and CDK Inhibition in Acute Myeloid Leukemia 18 samples shares inhibition, leukemia
- GSE301872 Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP (PDX samples from different disease statuses) 15 samples shares targeting, leukemia
- GSE303446 Beyond CD30 Targeting: Brentuximab Vedotin Triggers Immunogenic Cell Death and Antitumor Immunity in Mycosis Fungoides, Overcoming Resistance via BCL2 Inhibition 13 samples shares inhibition, targeting
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.